Search

Displaying results 2401 - 2410 of 8575 in total
  1. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]

  2. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … This type of virus is vastly used as vectors for gene therapy because they can infect dividing and quiescent cell integrating just the carried genes into the host genome without fully integrating into

  3. Drug

    Levosimendan

    go.drugbank.com/drugs/DB00922
    ApprovedInvestigationalWithdrawn

    Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triph...

  4. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. … Phenyl salicylate is used as a food additive in the USA [L2479]. This compound belongs to the class of organic compounds known as depsides and depsidones.

  5. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    [A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. … [A229113] Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.

  6. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Paritaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir first came on the market as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak.

  7. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.

  8. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. … The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

  9. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  10. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.